Recent advances in research on survivin and its molecular antagonists

Chinese Pharmacological Bulletin

Volumn 21, Issue 4, 2005, Pages 389-392

  Huang, Wei Lin ^a   Zhou, Xiang Jun ^a   Wang, Yong Xiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer; Molecular antagonist; Survivin; Target

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN INHIBITOR; SURVIVIN;

ARTICLE; DRUG TARGETING; MITOSIS; PROTEIN FAMILY; PROTEIN LOCALIZATION;

EID: 22444435858     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Altieri DC. Validating survivin as a cancer therapeutic target[J]. Nat Rev Cancer, 2003,3(1):46-54.
2. Verdecia MA, Huang H, Dutil E et al. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement[J]. Nat Struct Biol, 2000,7(7):602-8.
3. Li F, Ackermann EJ, Bennett CF et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function [J]. Nat Cell Biol, 1999,1(8):461-6.
4. Skoufias DA, Mollinari C, Lacroix FB et al. Human survivin is a kinetochore-associated passenger protein[J]. J Cell Biol, 2000, 151(7):1575-82.
5. Mahotka C, Wenzel M, Springer E et al. Survivin - ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties[J]. Cancer Res, 1999,59(24):6097-102.
6. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression[J]. Biochem J, 1999,344(2):305-11.
7. Zhao J, Tenev T, Martins LM et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner[J]. J Cell Sci, 2000,113(23):4363-71.
8. O'Connor DS, Wall NR, Porter AC et al. A p34 (cdc2) survival checkpoint in cancer[J]. Cancer Cell, 2002,2(1):43-54.
9. Uren AG, Wong L, Pakusch M et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype[J]. Curr Biol, 2000,10(21):1319-28.
10. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit[J]. FASEB J, 2001,15(14):2721 -3.
11. Shin S, Sung BJ, Cho YS et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspcase-3 and-7[J]. Biochemistry, 2001,40(4):1117-23.
12. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin[J]. Nature, 1998,396(6711): 580-4.
13. Grossman D, Kim PJ, Blanc-Brude OP et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53[J]. J Clin Invest, 2001,108 (7):991-9.
14. Blanc-Brude OP, Mesri M, Wall NR et al. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis[J]. Clin Cancer Res, 2003,9(7):2683-92.
15. Suzuki A, Ito T, Kawano H et al. Survivin initiates procaspase3/ p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death[J]. Oncogene, 2000,19(10):1346-53.
16. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF[J]. Proc Natl Acad Sci USA, 2002,99(7):4349-54.
17. Hoffman WH, Biade S, Zilfou JT et al. Transcriptional repression of the anti-apoptotic surviving gene by wild type p53[J]. J Biol Chem, 2002,277(5):3247-57.
18. Xia C, Xu Z, Yuan X et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides[J]. Mol Cancer Ther, 2002,1(9):687-94.
19. Eli Lilly and Company (LLY) Release: Antisense Drug Targeting Survivin Inhibits Growth Of Tumors In Animal Models[EB]. http://www.biospace.com/ news_story.cfm? StoryID = 14455220&full = 1.
20. Pennati M, Binda M, Colella G et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells[J]. Oncogene, 2004,23(2):386-94.
21. Pisarev V, Yu B, Salup R et al. Full-length dominant-negative survivin for cancer immunotherapy[J]. Clin Cancer Res, 2003,9 (17):6523-33.
22. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer[J]. J Transl Med, 2004,2(1):19.